SULFONYL-3-HETEROCYCLYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
申请人:Liu Kevin
公开号:US20090105303A1
公开(公告)日:2009-04-23
The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
本发明提供了一种I式化合物及其用于治疗与或受5-HT6受体相关的中枢神经系统疾病的用途。
Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands
作者:Kevin G. Liu、Jennifer R. Lo、Thomas A. Comery、Guo Ming Zhang、Jean Y. Zhang、Dianne M. Kowal、Deborah L. Smith、Li Di、Edward H. Kerns、Lee E. Schechter、Albert J. Robichaud
DOI:10.1016/j.bmcl.2009.04.108
日期:2009.6
Cognitive dysfunction is a characteristic of various forms of dementia such as Alzheimer's disease (AD) and a core feature of schizophrenia. As part of our continuing efforts to develop agents for cognitive enhancement, we have been focused on the 5-HT6 receptor-one of the emerging therapeutic targets in this area. Herein, we report the identification of a novel series of 3-piperidinyl-5-sulfonylindazole derivatives as potent 5-HT6 antagonists. The synthesis and SAR of this class of compounds are reported. (C) 2009 Elsevier Ltd. All rights reserved.
US7482461B2
申请人:——
公开号:US7482461B2
公开(公告)日:2009-01-27
[EN] SULFONYL-3-HETEROCYCLYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS<br/>[FR] DÉRIVÉS DE SULFONYL-3-HÉTÉROCYCLYLINDAZOLE UTILISÉS EN TANT QUE LIGANDS DE LA 5-HYDROXYTRYPTAMINE-6
申请人:WYETH CORP
公开号:WO2007117413A1
公开(公告)日:2007-10-18
[EN] The present invention provides a compound of formula (I) and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. [FR] La présente invention concerne un composé répondant à la formule I et l'utilisation dudit composé pour le traitement d'un trouble du système nerveux central associé au récepteur 5-HT6, ou modifié par ce récepteur. (Formule I)